Xiuchang Jiang - Sinopharm Group CFO VP
| SHTDFDelisted Stock | USD 2.70 0.00 0.00% |
CFO
Mr. Jiang Xiuchang is Chief Financial Officer, Vice President of Sinopharm Group Co., Ltd. He joined the Company in May 2010 as the chief financial officer, and was the vice president of the Company since July 2013. He has over 31 years of working experience, over 20 years of which is management experience in the pharmaceutical and healthcare products industry. Mr. Jiang obtained a bachelors degree in financial accounting from Zhongnan University of Economics and Law in July 1986, and graduated from the class for advanced studies of postgraduate courses in corporate management from the School of International Business Management of University of International Business and Economics in January 2005. Mr. Jiang was qualified as a senior economist and senior accountant. Mr. Jiang served at China National Pharmaceutical Group Co., Ltd. from July 1986 to March 2002, and was the deputy head of the department of information, reform office, finance department and deputy manager of the department of pharmacy. He was deputy head, head and chief financial officer of the finance department of China National Medicines Corporation Ltd. from March 2002 to May 2010. Mr. Jiang is currently the chairman of Sinopharm Holding Jiangxi Co., Ltd., Sinopharm Holding Shanxi Co., Ltd., Sinopharm Holding Inner Mongolia Co., Ltd., Sinopharm Holding Tianjin Co., Ltd. and Sinopharm Group Shanxi Co., Ltd. and China National Medicines Corporation Ltd., and the director of China National Accord Medicines Co., Ltd., Sinopharm Group Finance Co., Ltd., and the director and general manager of Sinopharm Holding Hong Kong Co., Ltd., and the executive director of Beijing Sinopharm Tianyuan Real Estate Property Management Co., Ltd. since 2013.
| Age | 59 |
| Tenure | 12 years |
| Phone | 86 21 2305 2666 |
| Web | https://www.sinopharmgroup.com.cn |
Sinopharm Group Management Efficiency
The company has return on total asset (ROA) of 0.0364 % which means that it generated a profit of $0.0364 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1319 %, meaning that it generated $0.1319 on every $100 dollars invested by stockholders. Sinopharm Group's management efficiency ratios could be used to measure how well Sinopharm Group manages its routine affairs as well as how well it operates its assets and liabilities.Sinopharm Group Co has accumulated 8.42 B in total debt with debt to equity ratio (D/E) of 0.89, which is about average as compared to similar companies. Sinopharm Group has a current ratio of 1.28, suggesting that it may have difficulties to pay its financial obligations in time and when they become due. Debt can assist Sinopharm Group until it has trouble settling it off, either with new capital or with free cash flow. So, Sinopharm Group's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sinopharm Group sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sinopharm to invest in growth at high rates of return. When we think about Sinopharm Group's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 1 records | CFO Age | ||
| Bo Shen | Shanghai Pharmaceuticals Holdin | 50 | |
Management Performance
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0364 |
Sinopharm Group Leadership Team
Elected by the shareholders, the Sinopharm Group's board of directors comprises two types of representatives: Sinopharm Group inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sinopharm. The board's role is to monitor Sinopharm Group's management team and ensure that shareholders' interests are well served. Sinopharm Group's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sinopharm Group's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Yijian Wu, Non-Executive Director | ||
| Xiaojuan Li, Chief Officer | ||
| Qingming Yu, Executive Director | ||
| Yong Liu, Chief Legal Advisor and VP | ||
| Shuangjun Xu, Vice President | ||
| Xiuchang Jiang, CFO VP | ||
| Wanyong Lian, Supervisor | ||
| Maisong Cai, Vice President |
Sinopharm Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Sinopharm Group a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0364 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.04 % | |||
| Current Valuation | 16.78 B | |||
| Shares Outstanding | 1.34 B | |||
| Shares Owned By Insiders | 0.01 % | |||
| Shares Owned By Institutions | 51.07 % | |||
| Price To Earning | 5.67 X | |||
| Price To Book | 0.88 X |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in Sinopharm Pink Sheet
If you are still planning to invest in Sinopharm Group check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sinopharm Group's history and understand the potential risks before investing.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |